Partnered Programs

Internal Development Pipeline

Our partnered pipeline includes drug candidates that we have out licensed to leading pharmaceutical and biotechnology companies, including Boehringer Ingelheim, Immunogen and Genmab. Our partners are developing one or more drug candidates that we discovered using our OGAP® platform.

Program

MOA

Territory

Partner

Discovery

Preclincal

IND-enabling

Phase I

Phase II

Program

OBT620

MOA

CD3 bispecific

Territory

M/R

partner

Phase 2

Program Summary

A DLL3/CD3 bispecific molecule to treat patients with small cell lung cancer and other neuroendocrine tumors that are positive for DLL3. Currently in phase I clinical trial.

Indications

SCLC and neuroendocrine tumors

Active Phase

Discovery

Preclincal

IND-enabling

Phase 1

Phase 2

This is some text inside of a div block.

partner

Program

OBT624

MOA

CD3 bispecific

Territory

M/R

partner

Phase 1

Program Summary

A bispecific molecule to treat patients with advanced solid tumors

Indications

Advanced solid tumors

Active Phase

Discovery

Preclincal

IND-enabling

Phase 1

Phase 2

This is some text inside of a div block.

partner

Program

OBT551

MOA

Undisclosed

Territory

M/R

partner

Discovery

Program Summary

Undisclosed molecule in pre-clinical development.

Indications

Undisclosed

Active Phase

Discovery

Preclincal

IND-enabling

Phase 1

Phase 2

This is some text inside of a div block.

partner

Program

5 programs

MOA

Undisclosed

Territory

M/R

partner

Discovery

Program Summary

OBT and Boehringer Ingelheim (BI) are collaborating to discover and validate novel selective tumor targets for BI’s unique T-cell engager, cancer vaccine and oncolytic virus platforms, enabled by OBTs OGAP® discovery. Five further programs enabled by OBTs OGAP® discovery platform are also undergoing validation.

Indications

Solid tumors

Active Phase

Discovery

Preclincal

IND-enabling

Phase 1

Phase 2

This is some text inside of a div block.

partner

Program

OBT700

MOA

IO mAB

Territory

M/R

partner

IND-enabling

Program Summary

A novel, first-in-class, immune checkpoint receptor agonist discovered and developed by OBT.

Indications

Solid tumors

Active Phase

Discovery

Preclincal

IND-enabling

Phase 1

Phase 2

This is some text inside of a div block.

partner

Program

OBT035

MOA

ADC

Territory

M/R

partner

Pre-clincal

Program Summary

An ADC specifically targeting ‘cold’ tumors that cannot be treated with check point inhibitors.

Indications

"Cold" and solid tumors

Active Phase

Discovery

Preclincal

IND-enabling

Phase 1

Phase 2

This is some text inside of a div block.

partner

Program

OBT227

MOA

ADC

Territory

M/R

partner

Pre-clincal

Program Summary

Novel ADC with strong cancer biology overexpressed in multiple solid tumors.

Indications

Solid tumors

Active Phase

Discovery

Preclincal

IND-enabling

Phase 1

Phase 2

This is some text inside of a div block.

partner

Program

OBT417

MOA

ADC

Territory

M/R

partner

Pre-clincal

Program Summary

Novel ADC with strong cancer biology overexpressed in multiple solid tumors.

Indications

Solid tumors

Active Phase

Discovery

Preclincal

IND-enabling

Phase 1

Phase 2

This is some text inside of a div block.

partner

Program

5 Programs

MOA

ADC

Territory

M/R

partner

Discovery

Program Summary

OBT and ImmunoGen are collaborating to develop novel antibidy drug conjugates coupling targets discovered using OBT's OGAP® discovery platform, with ImmunoGen's ADC linker-payload technology.

Indications

Hematological and solid tumors

Active Phase

Discovery

Preclincal

IND-enabling

Phase 1

Phase 2

This is some text inside of a div block.

partner

Program

2 Programs

MOA

CAR-T therapy

Territory

M/R

partner

Discovery

Program Summary

Through this collaboration, OBT will validate up to five novel oncology drug targets, previously identified using OBT’s OGAP® discovery platform, and generate antibodies against these. Kite and Gilead will have the exclusive right to develop and commercialize therapies based on these targets or antibodies.

Indications

Hematological and solid tumors

Active Phase

Discovery

Preclincal

IND-enabling

Phase 1

Phase 2

This is some text inside of a div block.

partner

M/R: Milestones and royalties; CAR-T: Chimeric Antigen Receptor T cell therapies

IO mAB: Immuno-oncology monoclonal antibody; ADC: Antibody drug conjugate; CAR-T therapy: Chimeric antigen receptor T cell therapy